Objective: Vitamin D receptor (VDR) activities have been noted for a number of B cell malignancies which showed varying sensitivities to vitamin D3 (1,25-dihydroxyvitamin D3, VD3, calcitriol) and its synthetic analogs. The objective of this study was to address the potential effects of VD3 and vitamin D3 analogs (VDAs) on the growth of Hodgkin's lymphoma (HL), a malignant pathology of B cell origin, in vitro.
Introduction
Vitamin D3 receptor signaling and its therapeutic perturbation with vitamin D3 (VD3, 1,25-dihydroxyvitamin, calcitriol) or vitamin D3 analogs (VDAs) have attracted much attention in cancer therapies, including treatment of B cell malignancies [1] . This is largely due to reports that showed strong association between VD3 deficiency and increased risk of both solid and liquid tumors [2] [3] [4] [5] . In subsets of B cell malignancies, low vitamin D is associated with worst prognosis-inferior event-free survival (EFS) and overall survival (OS) [2] . Studies showed that upon ligand (either VD3 or VDA) binding, VDR translocates to the nucleus where it modulates the expression of genes involved in cell growth and differentiation and apoptosis [6] .
Hodgkin's lymphoma (HL) is presented as a unique B cell neoplasm characterized by the presence of giant mononuclear Hodgkin's (H) and multinuclear ReedSternberg (RS)-HRS-cells, which make up less than 1% of the cellular infiltrate of the tumor microenvironment. Although a previous immunohistochemical study showed that VDR is highly expressed in 80% of HL cases [7] , very little is known about the influence of VD3/VDA-VDR interaction in this malignancy. Therefore, the goal of the current study was to investigate the effects of VD3/VDAs on the growth of HL via VDR expression, in vitro.
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Methods and materials Immunofluorescence
(US Biomax) consisting of 5-μm thick formaldehydefixed paraffin-embed histological sections was dewaxed with 2× with xylene (10 min each), rehydrated in 100, 80, 70, 50% ethanol (5 min each), and rinsed briefly in 1× PBS. Antigen retrieval was performed by heating sections for 20 min in 10 mM Na citrate (pH 6.0) at 95 °C followed by cooling for 20 min at room temperature. Sections were subsequently blocked with BSA (5% in Tris buffered saline (TBS, Sigma) then incubated overnight with anti-VDR mouse monoclonal antibody (Santa cruz; sc-13133) diluted at 1:100 in blocking buffer, at 4 °C. The tissue array was next washed 3× in TBS for 5 min each. This was followed by incubation in Dylight 594-conjugated mouse secondary antibody (Jackson Immunoresearch) diluted at 1:500 in blocking buffer, in the dark for 1 h at room temperature, subsequent washes as described. The sections were covered with number 1 coverslips containing 10 µL of mounting medium containing DAPI (Vector Labs). Staining was visualized on a Nikon Ti Eclipse inverted microscope. Images were captured with a CoolSNAP HQ2 CCD camera (Photometric Scientific) coupled to the microscope and processed with Adobe Photoshop 7.0 (Adobe, San Jose, CA) for clarity. All steps were same for negative controls with the exception of incubation in primary antibody.
Cell lines and cell cultures
The human HRS-derived cell lines HDLM2, KMH2 and L428 were obtained from the German Collection of Microorganisms and Cell Cultures (DSMZ), Department of Human and Animal Cell Cultures, Braunschweig, Germany. Hs445 was obtained from the American Tissue and Cell Collection (ATCC). L428 and KMH2 were cultured in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Gibco BRL, Gaithersburg, MD), 1% l-glutamine, and penicillin/streptomycin. Culture media for HDLM2 and Hs445 were similar but contained 20% heat-inactivated FBS. All cells were maintained in a humid environment of 5% CO 2 at 37 °C.
Vitamin D3 and its chemical analogs
VD3 or VDAs (calcipotriol and EB1089) were purchased from Cayman Chemicals and dissolved in DMSO to prepare a 10 mM stock which was aliquoted and stored at − 20 °C until ready to be used.
WST-1 cell proliferation assay
2 × 10 5 cells/mL plated in 96-well plates overnight and treated with 10 μM each of VD3, calcipotriol, and EB1089 for 72 h were incubated in indicated culture conditions. Cell growth was assessed with WST-1 cell proliferation assay (Roche, USA), according to manufacturer's instructions. In brief, 100 μL of treated cells were incubated with 10 µL of WST-1 reagent for 3 h following standard culture conditions. Absorbance was read at 450 nm on a Synergy H1 Hybrid microplate reader (BioTek). Cell growth (in percentages, %) was computed as ratio of absorbance (A450 nm) of treated cells relative to absorbance of control cells (DMSO) (A450 nm).
Preparation of nuclear extracts
L428 was plated at 1.5 × 10 5 cells/mL in 60-mm petri and incubated overnight. Cells were then treated with 10 μM each of VD3 or VDAs or vehicle (DMSO) and incubated for another 48 h. Treated cells were harvested by centrifugation for 5 min at 300×g, then washed 2× with ice-cold 1× PBS. Cell membrane was lysed by resuspending the cells in 500 μL ice-cold hypotonic buffer (20 mM Tris-HCl, pH 7.4, 10 mM NaCl, 3 mM MgCl 2 ) supplemented with Halt Protease and Phosphatase Inhibitor Cocktail (Thermofisher) and incubated on ice for 15 min, with occasional mixing. The lysate was then mixed with 25 μL of 10% NP 4 O by vortexing for 10 s. The homogenate was centrifuged at 3000 rpm for 10 min at 4 °C. Supernatant was transferred to a new tube and mix with RIPA (radioimmunoprecipitation) assay buffer (EMD Millipore) supplemented with protease and phosphatase inhibitor as described. Pellet (nuclear fraction) was resuspended in 150 μL ice-cold 1× RIPA buffer as described and incubated on ice, with vortexing at 10 min interval. Nuclear fraction was subsequently centrifuged for 30 min at 14,000×g at 4 °C and the supernatant aliquoted and stored at − 80 °C until ready for quantification by Bradford assay and analysis by sodium dodysulfate polyacrylamide (SDS-PAGE) gel and Western blot.
Preparation of total cell extracts
Treated cells were collected and rinse as described, then resuspended in ice-cold RIPA buffer supplemented with Halt Protease and Phosphatase Inhibitor Cocktail (Thermo Scientific, Rockford, IL, USA). Lysates were incubated for 5 min on ice with periodic mixing followed by centrifugation at 13,000×g for 10 min at 4 °C. Supernatant was transferred to new tube and stored at − 80 °C until ready for quantification by Bradford assay and SDS-PAGE and Western blot analyses.
Western blot
Protein concentrations were determined using Pierce Membrane was finally rinsed as described and protein signal was imaged using Odyssey-CLX imaging system (Li-COR).
Statistical analyses
Data analyses were performed using SAS 9.1.3, StatView 5, or JMP 4. Absorbance data reflection cell growth were presented as standard error of the mean (SEM) derived from triplicates. Analysis of variance (ANOVA) and F statistics were used to determine differences between the means as defined by p < 0.05. All experiments were repeated at least three times.
Results
Expression of VDR
The physiological responses of VD3/VDAs are mediated via VDR. Therefore, we analyze HL tissue sections and cell lines for the expression of VDR. Our immunofluorescence staining showed the expression of VDR by HRS cells on tissue array (Fig. 1a) . This observation is consistent with a previous immunohistochemical study which showed that VDR is expressed by almost 80% of HL cases [7] . VDR expression by HL cell lines was determined by Western blot analyses. Hs445, HDLM2, KMH2, and L428 showed relatively low expression but varying levels of VDR (Fig. 1b) .
Effects of VD analogs on cell growth
Previous studies indicated growth-limiting activities of VD3/VDAs on both normal and malignant B lymphoid cells [9] . Therefore, we next studied the effects of VD3 and the VDAs calcipotriol and EB1089 on the growth of HL cells HDLM2 and L428. One-way ANOVA on data obtained from WST-1 cell proliferation assay revealed decreases in growth of cells treated with either VD3 or VDAs, after 72 h (Fig. 2) . As expected, EB1089 showed a greater effect in reducing growth of both HDLM2 and L428. modulates the expression of target genes. Therefore, we tested the effects of VD3/VDAs on the nuclear accumulation of VDR by Western blot. L428 cells treated with 10 µM of VDAs for 48 h showed only a modest increase in nuVDR over either DMSO-or VD3-treated cells (DMSO and VD3 showed comparable effects on nuVDR)- Fig. 3 . The modest changes in nuVDR in our study may be due to very low basal levels of VDR in unstimulated L428 cells.
Nuclear accumulation
Discussion
Our data showed that VDR is expressed by HL cell lines and primary HRS cells. The HL cell lines used in this study showed low but varying levels of VDR expression. Also, expression of VDR by HRS cells is qualitatively in accordance with the study by Renne et al. [7] . The results also showed that VD3/VDAs reduced growth of HL, in vitro, 72 h after treatment. The reduced cell growth of L428 was associated with modest increases in nuVDR in response to treatment with calcipotriol and EB1089.
In our study, the dose of VD3 (10 µM) used to elicit only modest decrease in cell growth is considered to be at supra-physiological concentration and this may be a consequence of low basal levels of VDR expression in unstimulated cells. In follicular low grade non-Hodgkin's lymphoma (NHL), low levels of VDR expression was detected in primary tumor cells and cell lines (SU-DHL4 and SU-DUL5), however high concentration of VD3 was used to produce growth restriction in vitro [10] . In contrast, cellular models of acute myeloid leukemia (HL-60 cells) and diffuse large B cell lymphomas (DOHH2, K422) express high levels of VDR and display moderate cytotoxicity and pro-apoptotic responses upon exposure to nanomolar concentrations of VD3 (and VDAs) [11] . These observations suggest the levels of VDR expression in unstimulated cells may influence extent of VD3 sensitivity of some B malignancies. Additionally, while VD3 fail to stimulate nuVDR in our study (compare to DMSO), nanomolar concentrations of VD3 resulted in significantly higher nuVDR in other B cell neoplasms [11] .
Because low VDR expression may hinder anti-tumor activities of VD3, it will be important to develop strategies to induce increased VDR expression. One of these approaches involved ligand-stimulated upregulation of receptor. It has been reported that VD3 stimulation resulted in the VDR upregulation [12, 13] . However, VD3-stimulated upregulation may not be possible in all types of VDR-positive neoplasms. Other approaches include the use of a non-vitamin inducer. Progesterone directly induced upregulation of VDR expression in T lymphocytes, via binding progesterone receptorbinding elements in the intron region after the first noncoding exon of the VDR gene [14] . In addition, progesterone enhanced the anti-tumor activities of VD3 by upregulating of VDR expression in endometrial cancer cells [15] . Inducer-stimulation of VDR expression may be useful for cancer therapy in which primary tumor cells exhibit low levels of VDR expression. Application of supra-physiological concentration of VD3 to suppress tumor growth in vivo can promote hypercalcemia and hypercalciuria [16] , leading to hardening of soft tissues. As a result, low-calcemic VDAs were developed [11, 17] . Two of these molecules, calcipotriol and EB1089 showed anti-tumor activities in a number of studies [18, 19] . However, EB1089 appeared to be amongst the most potent anti-tumor VDA [20] . In our study, treatment with either calcipotriol or EB1089 resulted in significant decrease in cell growth which also correlated with greater nuVDR. Future studies are warranted to determine the underlying mechanism(s) by which calcipotriol and EB1089 limit growth of HL.
Limitations
Our study has limitations that must be considered. A positive control such as the breast cancer cell line MCF7 or the myeloid leukemia cell HL-60, both of which previously showed significant sensitivities to VD3/VDAs were not included in our study. The current study also suffers from a lack of cell cycle analysis and other molecular details.
